FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3082303142> ?p ?o ?g. }

• W3082303142 abstract "Background: ErbB receptor tyrosine kinases: EGFR (ErbB1), HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4) are part of a complex network activating signaling pathways involved in cell growth and survival. Mutations causing errant ErbB activation is an oncodriver in many cancers. Inhibitors targeting ErbB mutations have transformed patient outcomes; however, treatment resistance develops rapidly and crosstalk between ErbB family members is associated with acquired resistance. The development of next-generation agents targeting multiple ErbB receptors has shown promise but has been limited by toxicity and poor brain penetration. EO1001 is a first-in-class, oral, brain penetrating, irreversible pan-ErbB inhibitor with superior CNS penetration targeting ErbB1, ErbB2 and ErbB4. Preclinical data suggests a favorable pharmacokinetic and toxicity profile and promising activity against ErbB-driven cancers in patient-derived xenograft models. Methods: This study examines the safety and tolerability of EO1001 to define a recommended dose for advanced human clinical trials and to assess efficacy. Male or female adult participants with confirmed ErbB-positive cancer, including patients with CNS disease involvement, who have progressed after standard of care therapy, with adequate bone marrow, renal and liver function are eligible. An accelerated dose-escalation design is employed. One subject per dose cohort will be recruited until drug related toxicity (%gt=G2) is observed in the first dosing cycle, after which the dose escalation scheme will revert to a 3+3 design in a modified-Fibonacci dose-escalation scheme to determine the maximum tolerated dose (MTD). Dose Escalation: Cycle 1: Patients will receive a single dose EO1001 on day 1 and single dose pharmacokinetics will be performed. Beginning on day 8, EO1001 will be administered once daily for 21 days; multi-dose pharmacokinetics will be performed. Cycles 2-6: Oral EO1001 will be administered once daily in continuous 28-day cycles for up to 20 weeks. MTD Expansion: Oral EO1001 will be administered once daily at the MTD in continuous 28-day cycles for up to 6 cycles (24 weeks). Toxicity will be assessed based on NCI CCTCAEv5 and tumor response will be assessed by RECIST 1.1 or RANO for CNS disease. CNS exposure will be evaluated in patients via CSF collection with confirmed CNS disease involvement. Citation Format: Jeffrey A. Bacha, Dennis Brown, Sarath Kanekal, Ian Nisbet, Neil Sankar, Wang Shen, Helen Wheeler, Kathy Skoff, Zhen Zhong Wang. An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and antitumor activity of once-daily oral treatment with EO1001, a novel irreversible pan-ErbB inhibitor with promising brain penetration, in patients with advanced cancer [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT154." @default.
• W3082303142 created "2020-09-08" @default.
• W3082303142 creator A5006057885 @default.
• W3082303142 creator A5013583484 @default.
• W3082303142 creator A5014794937 @default.
• W3082303142 creator A5016462836 @default.
• W3082303142 creator A5034088885 @default.
• W3082303142 creator A5050440486 @default.
• W3082303142 creator A5064134740 @default.
• W3082303142 creator A5066896961 @default.
• W3082303142 creator A5091035596 @default.
• W3082303142 date "2020-08-13" @default.
• W3082303142 modified "2023-10-17" @default.
• W3082303142 title "Abstract CT154: An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and antitumor activity of once-daily oral treatment with EO1001, a novel irreversible pan-ErbB inhibitor with promising brain penetration, in patients with advanced cancer" @default.
• W3082303142 doi "https://doi.org/10.1158/1538-7445.am2020-ct154" @default.
• W3082303142 hasPublicationYear "2020" @default.
• W3082303142 type Work @default.
• W3082303142 sameAs 3082303142 @default.
• W3082303142 citedByCount "0" @default.
• W3082303142 crossrefType "proceedings-article" @default.
• W3082303142 hasAuthorship W3082303142A5006057885 @default.
• W3082303142 hasAuthorship W3082303142A5013583484 @default.
• W3082303142 hasAuthorship W3082303142A5014794937 @default.
• W3082303142 hasAuthorship W3082303142A5016462836 @default.
• W3082303142 hasAuthorship W3082303142A5034088885 @default.
• W3082303142 hasAuthorship W3082303142A5050440486 @default.
• W3082303142 hasAuthorship W3082303142A5064134740 @default.
• W3082303142 hasAuthorship W3082303142A5066896961 @default.
• W3082303142 hasAuthorship W3082303142A5091035596 @default.
• W3082303142 hasBestOaLocation W30823031421 @default.
• W3082303142 hasConcept C112705442 @default.
• W3082303142 hasConcept C197934379 @default.
• W3082303142 hasConcept C2778375690 @default.
• W3082303142 hasConcept C71924100 @default.
• W3082303142 hasConcept C98274493 @default.
• W3082303142 hasConceptScore W3082303142C112705442 @default.
• W3082303142 hasConceptScore W3082303142C197934379 @default.
• W3082303142 hasConceptScore W3082303142C2778375690 @default.
• W3082303142 hasConceptScore W3082303142C71924100 @default.
• W3082303142 hasConceptScore W3082303142C98274493 @default.
• W3082303142 hasLocation W30823031421 @default.
• W3082303142 hasOpenAccess W3082303142 @default.
• W3082303142 hasPrimaryLocation W30823031421 @default.
• W3082303142 hasRelatedWork W2037576960 @default.
• W3082303142 hasRelatedWork W2074207917 @default.
• W3082303142 hasRelatedWork W2080612540 @default.
• W3082303142 hasRelatedWork W2154883587 @default.
• W3082303142 hasRelatedWork W2914758292 @default.
• W3082303142 hasRelatedWork W4205587618 @default.
• W3082303142 hasRelatedWork W4253098345 @default.
• W3082303142 hasRelatedWork W4296087748 @default.
• W3082303142 hasRelatedWork W4366822339 @default.
• W3082303142 hasRelatedWork W1962564742 @default.
• W3082303142 isParatext "false" @default.
• W3082303142 isRetracted "false" @default.
• W3082303142 magId "3082303142" @default.
• W3082303142 workType "article" @default.